JP2018518527A - Ｔ細胞療法によるｃｍｖ網膜炎の治療方法 - Google Patents

Ｔ細胞療法によるｃｍｖ網膜炎の治療方法 Download PDF

Info

Publication number
JP2018518527A
JP2018518527A JP2017567429A JP2017567429A JP2018518527A JP 2018518527 A JP2018518527 A JP 2018518527A JP 2017567429 A JP2017567429 A JP 2017567429A JP 2017567429 A JP2017567429 A JP 2017567429A JP 2018518527 A JP2018518527 A JP 2018518527A
Authority
JP
Japan
Prior art keywords
allogeneic
cells
cmv
cell population
human patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017567429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518527A5 (enExample
Inventor
ジョン オレイリ リチャード
ジョン オレイリ リチャード
エリザベス プロコプ スーザン
エリザベス プロコプ スーザン
ドウブロビナ エカテリーナ
ドウブロビナ エカテリーナ
コエフネ グエンサー
コエフネ グエンサー
ナスリーン ハサン アイシャ
ナスリーン ハサン アイシャ
キス シラード
キス シラード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of JP2018518527A publication Critical patent/JP2018518527A/ja
Publication of JP2018518527A5 publication Critical patent/JP2018518527A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
JP2017567429A 2015-06-26 2016-06-21 Ｔ細胞療法によるｃｍｖ網膜炎の治療方法 Pending JP2018518527A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562185558P 2015-06-26 2015-06-26
US62/185,558 2015-06-26
US201562191304P 2015-07-10 2015-07-10
US62/191,304 2015-07-10
PCT/US2016/038530 WO2016209816A1 (en) 2015-06-26 2016-06-21 Methods of treating cmv retinitis by t cell therapy

Publications (2)

Publication Number Publication Date
JP2018518527A true JP2018518527A (ja) 2018-07-12
JP2018518527A5 JP2018518527A5 (enExample) 2019-08-08

Family

ID=56404300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567429A Pending JP2018518527A (ja) 2015-06-26 2016-06-21 Ｔ細胞療法によるｃｍｖ網膜炎の治療方法

Country Status (6)

Country Link
US (2) US10342864B2 (enExample)
EP (2) EP3756676B1 (enExample)
JP (1) JP2018518527A (enExample)
CN (1) CN107921065A (enExample)
HK (1) HK1254397A1 (enExample)
WO (1) WO2016209816A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220016132A (ko) * 2019-05-28 2022-02-08 도요보 가부시키가이샤 폴리에스테르 필름, 적층 필름 및 그 용도

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
EP3700553A1 (en) 2017-10-23 2020-09-02 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
WO2021021937A1 (en) * 2019-07-29 2021-02-04 Baylor College Of Medicine Antigen-specific t cell banks and methods of making and using the same therapeutically
RU2740943C1 (ru) * 2020-03-23 2021-01-21 Борис Сергеевич Першин Способ лечения цитомегаловирусного ретинита после трансплантации гемопоэтических стволовых клеток

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595978A (en) * 1990-08-16 1997-01-21 Isis Pharmaceuticals, Inc. Composition and method for treatment of CMV retinites
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6156317A (en) 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US7041442B1 (en) 1999-06-04 2006-05-09 Florian Kern Peptides for vaccinating against human CMV
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
DE60109633T2 (de) 2000-10-20 2006-01-19 City Of Hope, Duarte Immunreaktive peptidische ctl-epitope aus dem menschlichen cytomegalovirus pp150
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
JP2005517637A (ja) * 2001-11-29 2005-06-16 セラコス・インコーポレイテッド 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法
EP1483575A2 (en) 2002-02-28 2004-12-08 Intercell AG Methods for isolating ligands e.g. t cell epitopes
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
CA2728739C (en) 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
MX2011005691A (es) 2008-11-28 2011-07-20 Univ Emory Metodos para el tratamiento de infecciones y tumores.
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB0917094D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US20140303092A1 (en) * 2011-10-26 2014-10-09 Chimerix, Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
GB201121308D0 (en) * 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2017003763A1 (en) * 2015-06-27 2017-01-05 Memorial Sloan Kettering Cancer Center Methods of treating glioblastoma multiforme by t cell therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OPHTHALMIC SURG. LASERS IMAGING RETINA, (2015), 46, [1], P.80-82, JPN5018003679, ISSN: 0004398299 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220016132A (ko) * 2019-05-28 2022-02-08 도요보 가부시키가이샤 폴리에스테르 필름, 적층 필름 및 그 용도
KR102815003B1 (ko) 2019-05-28 2025-05-30 도요보 가부시키가이샤 폴리에스테르 필름, 적층 필름 및 그 용도

Also Published As

Publication number Publication date
EP3313419A1 (en) 2018-05-02
WO2016209816A1 (en) 2016-12-29
HK1254397A1 (zh) 2019-07-19
EP3313419B1 (en) 2020-08-19
US11103577B2 (en) 2021-08-31
CN107921065A (zh) 2018-04-17
EP3756676A1 (en) 2020-12-30
US20200016261A1 (en) 2020-01-16
US20170128565A1 (en) 2017-05-11
US10342864B2 (en) 2019-07-09
EP3756676B1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
US11103577B2 (en) Methods of treating CMV retinitis by T cell therapy
Griffiths et al. Pathogenesis of human cytomegalovirus in the immunocompromised host
JP2022184924A (ja) 免疫応答を増強するためのメッセンジャーリボ核酸及びその使用方法
Stittelaar et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques
Bergmann et al. Impaired T cell immunity in B cell-deficient mice following viral central nervous system infection
Herz et al. Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells
Riddell et al. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection
Chentoufi et al. Combinatorial herpes simplex vaccine strategies: from bedside to bench and back
Chentoufi et al. Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections
CN112638410A (zh) 诱导t细胞的疫苗组合物组合及其用途
Morrison et al. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1
RS58891B1 (sr) Uslovno replicirajući citomegalovirus kao vakcina za cmv
Dittmer et al. Friend retrovirus studies reveal complex interactions between intrinsic, innate and adaptive immunity
JP2016501023A (ja) 条件付き複製ウイルスベクター
Deshpande et al. Herpetic eye disease: immunopathogenesis and therapeutic measures
Wu et al. A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis
Xu et al. Ocular cytomegalovirus latency exacerbates the development of choroidal neovascularization
Gmyrek et al. Herpes simplex virus 1 (HSV-1) 0ΔNLS live-attenuated vaccine protects against ocular HSV-1 infection in the absence of neutralizing antibody in HSV-1 gB T cell receptor-specific transgenic mice
Giovannoni Targeting Epstein–Barr virus in multiple sclerosis: when and how?
Wickham et al. Molecular mimicry versus bystander activation: herpetic stromal keratitis
Duarte et al. Tackling cutaneous herpes simplex virus disease with topical immunomodulators—a call to action
Royer et al. Herpesvirus-associated lymphadenitis distorts fibroblastic reticular cell microarchitecture and attenuates CD8 T cell responses to neurotropic infection in mice lacking the STING-IFNα/β defense pathways
Xu et al. Inflammation and outer blood-retina barrier (BRB) compromise following choroidal murine cytomegalovirus (MCMV) infections
Jacobson et al. Lymphoma: risk and response after solid organ transplant
Zöllner et al. Cytomegalovirus retinitis in children and adolescents with acute leukemia following allogeneic hematopoietic stem cell transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201201